Thomas Sabia
Corporate Officer/Principal chez QUINCE THERAPEUTICS, INC.
Profil
Thomas Sabia is currently the Chief Commercial Officer at Quince Therapeutics, Inc. He previously held the same position at EryDel SpA from 2022 to 2023.
Mr. Sabia has an undergraduate degree and an MBA from Salisbury State University.
Postes actifs de Thomas Sabia
| Sociétés | Poste | Début |
|---|---|---|
| QUINCE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/10/2023 |
Anciens postes connus de Thomas Sabia
| Sociétés | Poste | Fin |
|---|---|---|
EryDel SpA
 EryDel SpA Medical SpecialtiesHealth Technology EryDel SpA offers medical research. It develops drugs and diagnostics delivered through human red blood cells via a medical device technology. The company was founded by Luigia Rossi and Mauro Magnani in 2007 and is headquartered in Bresso, Italy. | Corporate Officer/Principal | 01/10/2023 |
Formation de Thomas Sabia
| Salisbury State University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| QUINCE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
EryDel SpA
EryDel SpA Medical SpecialtiesHealth Technology EryDel SpA offers medical research. It develops drugs and diagnostics delivered through human red blood cells via a medical device technology. The company was founded by Luigia Rossi and Mauro Magnani in 2007 and is headquartered in Bresso, Italy. | Health Technology |
